{"id":4292,"date":"2025-09-29T14:47:14","date_gmt":"2025-09-29T14:47:14","guid":{"rendered":"https:\/\/cms.core-way.de\/?p=4292"},"modified":"2025-09-29T14:47:20","modified_gmt":"2025-09-29T14:47:20","slug":"o-ingrediente-ativo-tulisokibart-uma-esperanca-para-os-doentes-com-ced","status":"publish","type":"post","link":"https:\/\/cms.core-way.de\/pt\/der-wirkstoff-tulisokibart-eine-hoffnung-fuer-patientinnen-mit-ced\/","title":{"rendered":"O princ\u00edpio ativo Tulisokibart: Esperan\u00e7a para os doentes com DII?"},"content":{"rendered":"<h1 class=\"wp-block-heading\"><span style=\"color: var(--ast-global-color-3);\" class=\"stk-highlight\">O princ\u00edpio ativo Tulisokibart: Esperan\u00e7a para os doentes com DII?<\/span><\/h1>\n\n\n\n<div class=\"wp-block-stackable-text stk-block-text stk-block stk-1933731\" data-block-id=\"1933731\"><style>.stk-1933731 {margin-bottom:0px !important;}.stk-1933731 .stk-block-text__text{font-family:\"Figtree\", Sans-serif !important;}<\/style><p class=\"stk-block-text__text\">A doen\u00e7a de Crohn e a colite ulcerosa evoluem de forma muito diferente em cada doente. Por conseguinte, \u00e9 importante utilizar diferentes abordagens terap\u00eauticas para obter a melhor melhoria poss\u00edvel da qualidade de vida. Existem atualmente estudos sobre um novo princ\u00edpio ativo que conseguiu a remiss\u00e3o em alguns doentes com DII. Explicamos de que princ\u00edpio ativo se trata e como funciona.<\/p><\/div>\n\n\n\n<div class=\"wp-block-stackable-image stk-block-image stk-block stk-a844add\" data-block-id=\"a844add\"><figure><span class=\"stk-img-wrapper stk-image--shape-stretch\"><img loading=\"lazy\" decoding=\"async\" class=\"stk-img wp-image-4298\" src=\"https:\/\/cms.core-way.de\/wp-content\/uploads\/2025\/09\/48.png\" width=\"1366\" height=\"768\" alt=\"A imagem mostra uma caixa de medicamentos cor de laranja no canto inferior direito. Dela saem v\u00e1rios comprimidos, que s\u00e3o compridos e redondos e t\u00eam cores diferentes, como o branco, o cor-de-rosa e o amarelo. Os comprimidos encontram-se sobre um fundo azul. A imagem \u00e9 simb\u00f3lica. Os princ\u00edpios activos tamb\u00e9m s\u00e3o administrados sob a forma de comprimidos. A imagem \u00e9 utilizada simbolicamente para a subst\u00e2ncia ativa tulisokibart, que \u00e9 discutida em mais pormenor no artigo em que a imagem \u00e9 utilizada. Tamb\u00e9m explica como a subst\u00e2ncia actua em doentes com DII\" srcset=\"https:\/\/cms.core-way.de\/wp-content\/uploads\/2025\/09\/48.png 1366w, https:\/\/cms.core-way.de\/wp-content\/uploads\/2025\/09\/48-300x169.png 300w, https:\/\/cms.core-way.de\/wp-content\/uploads\/2025\/09\/48-1024x576.png 1024w, https:\/\/cms.core-way.de\/wp-content\/uploads\/2025\/09\/48-768x432.png 768w, https:\/\/cms.core-way.de\/wp-content\/uploads\/2025\/09\/48-480x270.png 480w, https:\/\/cms.core-way.de\/wp-content\/uploads\/2025\/09\/48-18x10.png 18w\" sizes=\"auto, (max-width: 1366px) 100vw, 1366px\" \/><\/span><\/figure><\/div>\n\n\n\n<div class=\"wp-block-stackable-columns aligncenter stk-block-columns stk-block stk-adb644b\" data-block-id=\"adb644b\"><div class=\"stk-row stk-inner-blocks has-text-align-left stk-block-content stk-content-align stk-adb644b-column\">\n<div class=\"wp-block-stackable-column stk-block-column stk-column stk-block stk-cf0fc90\" data-v=\"4\" data-block-id=\"cf0fc90\"><div class=\"stk-column-wrapper stk-block-column__content stk-container stk-cf0fc90-container stk--no-background stk--no-padding\"><div class=\"stk-block-content stk-inner-blocks stk-cf0fc90-inner-blocks\">\t\t\t\t<div class=\"wp-block-uagb-table-of-contents uagb-toc__align-left uagb-toc__columns-1  uagb-block-c8c16133\"\n\t\t\t\t\tdata-scroll= \"1\"\n\t\t\t\t\tdata-offset= \"30\"\n\t\t\t\t\tstyle=\"\"\n\t\t\t\t>\n\t\t\t\t<div class=\"uagb-toc__wrap\">\n\t\t\t\t\t\t<div class=\"uagb-toc__title\">\n\t\t\t\t\t\t\t<strong><span style=\"color: var(--ast-global-color-3)\" class=\"stk-highlight\">Conte\u00fado<\/span><\/strong>\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<div class=\"uagb-toc__list-wrap\">\n\t\t\t\t\t\t<ol class=\"uagb-toc__list\"><li class=\"uagb-toc__list\"><a href=\"#der-wirkstoff-tulisokibart-eine-hoffnung-f\u00fcr-patientinnen-mit-ced\" class=\"uagb-toc-link__trigger\">O princ\u00edpio ativo Tulisokibart: Esperan\u00e7a para os doentes com DII?<\/a><ul class=\"uagb-toc__list\"><li class=\"uagb-toc__list\"><a href=\"#neuer-wirkstoff-tulisokibart\" class=\"uagb-toc-link__trigger\">Nova subst\u00e2ncia ativa: Tulisokibart<\/a><li class=\"uagb-toc__list\"><li class=\"uagb-toc__list\"><a href=\"#doch-wie-wirkt-dieser-wirkstoff-genauer-im-k\u00f6rper\" class=\"uagb-toc-link__trigger\">Mas como \u00e9 que este ingrediente ativo funciona exatamente no corpo?<\/a><li class=\"uagb-toc__list\"><li class=\"uagb-toc__list\"><a href=\"#warum-ist-tulisokibart-f\u00fcr-ced-ein-m\u00f6glicher-neuer-wirkstoff\" class=\"uagb-toc-link__trigger\">Porque \u00e9 que o tulisokibart \u00e9 um potencial novo medicamento para a DII?<\/a><li class=\"uagb-toc__list\"><li class=\"uagb-toc__list\"><a href=\"#wie-wurde-der-wirkstoff-bei-colitis-ulcerosa-eingesetzt\" class=\"uagb-toc-link__trigger\">Como \u00e9 que a subst\u00e2ncia ativa tem sido utilizada na colite ulcerosa?<\/a><ul class=\"uagb-toc__list\"><li class=\"uagb-toc__list\"><a href=\"#welche-ergebnisse-konnten-damit-bei-colitis-ulcerosa-erzielt-werden\" class=\"uagb-toc-link__trigger\">Que resultados foram obtidos com a colite ulcerosa?<\/a><\/li><\/ul><li class=\"uagb-toc__list\"><a href=\"#so-wurde-tulisokibart-bei-morbus-crohn-eingesetzt\" class=\"uagb-toc-link__trigger\">Como o Tulisokibart foi utilizado para a doen\u00e7a de Crohn<\/a><ul class=\"uagb-toc__list\"><li class=\"uagb-toc__list\"><a href=\"#diese-ergebnisse-gab-es-bei-morbus-crohn\" class=\"uagb-toc-link__trigger\">Estes foram os resultados para a doen\u00e7a de Crohn<\/a><\/li><\/ul><li class=\"uagb-toc__list\"><a href=\"#ausblick-f\u00fcr-die-zukunft\" class=\"uagb-toc-link__trigger\">Perspectivas para o futuro<\/a><li class=\"uagb-toc__list\"><li class=\"uagb-toc__list\"><a href=\"#quickfacts\" class=\"uagb-toc-link__trigger\">Factos r\u00e1pidos:<\/a><ul class=\"uagb-toc__list\"><li class=\"uagb-toc__list\"><a href=\"#quellen\" class=\"uagb-toc-link__trigger\">Fontes<\/a><\/li><\/ul><li class=\"uagb-toc__list\"><a href=\"#weitere-interessante-artikel\" class=\"uagb-toc-link__trigger\">Mais artigos interessantes<\/a><li class=\"uagb-toc__list\"><li class=\"uagb-toc__list\"><a href=\"#toc_6a78e2b8c2749\" class=\"uagb-toc-link__trigger\"><\/a><\/ul><\/ol>\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t<\/div><\/div><\/div>\n<\/div><\/div>\n\n\n\n<div class=\"wp-block-stackable-heading stk-block-heading stk-block-heading--v2 stk-block stk-4aee19d\" id=\"span-style-color-var-ast-global-color-3-class-stk-highlight-uberschrift-1-u-span\" data-block-id=\"4aee19d\"><style>.stk-4aee19d .stk-block-heading__text{font-family:\"Figtree\", Sans-serif !important;}<\/style><h2 class=\"stk-block-heading__text\"><strong><span style=\"color: var(--ast-global-color-3);\" class=\"stk-highlight\">Nova subst\u00e2ncia ativa: Tulisokibart<\/span><\/strong><\/h2><\/div>\n\n\n\n<div class=\"wp-block-stackable-text stk-block-text stk-block stk-fa6f5f5\" data-block-id=\"fa6f5f5\"><style>.stk-fa6f5f5 {margin-bottom:18px !important;}.stk-fa6f5f5 .stk-block-text__text{font-family:\"Figtree\", Sans-serif !important;}<\/style><p class=\"stk-block-text__text\">O novo ingrediente ativo tulisokibart \u00e9 um dos muitos anticorpos monoclonais cujo efeito nas doen\u00e7as inflamat\u00f3rias cr\u00f3nicas do intestino est\u00e1 a ser investigado. Este anticorpo actua contra a TL1A, tamb\u00e9m conhecida como ligando 1A do tipo necrose tumoral, uma citocina que causa inflama\u00e7\u00e3o no organismo. As citocinas s\u00e3o uma forma de subst\u00e2ncia mensageira respons\u00e1vel pela transmiss\u00e3o de sinais entre as c\u00e9lulas.<\/p><\/div>\n\n\n\n<div class=\"wp-block-stackable-heading stk-block-heading stk-block-heading--v2 stk-block stk-89059c1\" id=\"strong-span-style-color-var-ast-global-color-3-class-stk-highlight-doch-wie-wirkt-dieser-wirkstoff-genauer-im-korper-span-strong\" data-block-id=\"89059c1\"><style>.stk-89059c1 .stk-block-heading__text{font-family:\"Figtree\", Sans-serif !important;}<\/style><h2 class=\"stk-block-heading__text\"><strong><span style=\"color: var(--ast-global-color-3);\" class=\"stk-highlight\">Mas como \u00e9 que este ingrediente ativo funciona exatamente no corpo?<\/span><\/strong><\/h2><\/div>\n\n\n\n<div class=\"wp-block-stackable-text stk-block-text stk-block stk-c2a6d31\" data-block-id=\"c2a6d31\"><style>.stk-c2a6d31 {margin-bottom:18px !important;}.stk-c2a6d31 .stk-block-text__text{font-style:normal !important;font-family:\"Figtree\", Sans-serif !important;}<\/style><p class=\"stk-block-text__text\">Em caso de inflama\u00e7\u00e3o intestinal, \u00e9 frequentemente detectado um aumento da concentra\u00e7\u00e3o da citocina TL1A. A TL1A reage com o recetor de morte 3 (DR3). O DR3 \u00e9 uma prote\u00edna transmembranar que actua como mediador de reac\u00e7\u00f5es inflamat\u00f3rias. Se a TL1A entrar em contacto com o DR3, s\u00e3o libertadas mais citocinas nesta zona. Em geral, isto leva a uma inflama\u00e7\u00e3o neste local.<\/p><\/div>\n\n\n\n<div class=\"wp-block-stackable-heading stk-block-heading stk-block-heading--v2 stk-block stk-26530cc\" id=\"span-style-color-var-ast-global-color-3-class-stk-highlight-warum-ist-tulisokibart-fur-ced-ein-moglicher-neuer-wirkstoff-span\" data-block-id=\"26530cc\"><h2 class=\"stk-block-heading__text\"><span style=\"color: var(--ast-global-color-3);\" class=\"stk-highlight\">Porque \u00e9 que o tulisokibart \u00e9 um potencial novo medicamento para a DII?<\/span><\/h2><\/div>\n\n\n\n<div class=\"wp-block-stackable-text stk-block-text stk-block stk-1af180e\" data-block-id=\"1af180e\"><style>.stk-1af180e {margin-bottom:18px !important;}<\/style><p class=\"stk-block-text__text\">Em circunst\u00e2ncias normais, a TL1A \u00e9 produzida apenas em pequenas quantidades, por exemplo, quando h\u00e1 um aumento da quantidade de lipopolissac\u00e1ridos - certos componentes celulares bacterianos - no organismo. No entanto, nas doen\u00e7as inflamat\u00f3rias cr\u00f3nicas do intestino, como a doen\u00e7a de Crohn e a colite ulcerosa, a forma\u00e7\u00e3o do ligando 1A semelhante \u00e0 necrose tumoral \u00e9 perturbada, levando a uma produ\u00e7\u00e3o excessiva da subst\u00e2ncia. O novo ingrediente ativo tulisokibart, que actua como um anticorpo contra a TL1A, demonstrou um efeito positivo na conten\u00e7\u00e3o da inflama\u00e7\u00e3o em estudos. O tulisokibart liga-se ao TL1A, impedindo-o de se ligar ao recetor de morte 3. A rea\u00e7\u00e3o inflamat\u00f3ria \u00e9 assim inibida.<\/p><\/div>\n\n\n\n<div class=\"wp-block-stackable-heading stk-block-heading stk-block-heading--v2 stk-block stk-3b0eff0\" id=\"strong-span-style-color-var-ast-global-color-3-class-stk-highlight-wie-wurde-der-wirkstoff-bei-colitis-ulcerosa-eingesetzt-span-strong\" data-block-id=\"3b0eff0\"><h2 class=\"stk-block-heading__text\"><strong><span style=\"color: var(--ast-global-color-3);\" class=\"stk-highlight\">Como \u00e9 que a subst\u00e2ncia ativa tem sido utilizada na colite ulcerosa?<\/span><\/strong><\/h2><\/div>\n\n\n\n<div class=\"wp-block-stackable-text stk-block-text stk-block stk-7c1fc38\" data-block-id=\"7c1fc38\"><style>.stk-7c1fc38 {margin-bottom:19px !important;}<\/style><p class=\"stk-block-text__text\">O estudo de fase 2 investigou se o anticorpo tulisokibart pode favorecer a remiss\u00e3o em doentes com colite ulcerosa com uma evolu\u00e7\u00e3o moderada a grave. Os doentes tinham tamb\u00e9m em comum o facto de j\u00e1 terem sido tratados com um medicamento biol\u00f3gico sem resposta ou de terem uma evolu\u00e7\u00e3o da colite ulcerosa dependente de ester\u00f3ides.  Antes de serem classificados nas respectivas coortes, os doentes foram tamb\u00e9m submetidos a um novo tipo de teste. Este fornece informa\u00e7\u00f5es sobre se os doentes responder\u00e3o melhor a esta forma de terapia do que a outras, com base em factores gen\u00e9ticos.<\/p><\/div>\n\n\n\n<div class=\"wp-block-stackable-heading stk-block-heading stk-block-heading--v2 stk-block stk-7b32346\" id=\"ub-3-das-column-feature-fur-vor-und-nachteile-oder-produktansichten\" data-block-id=\"7b32346\"><style>.stk-7b32346 .stk-block-heading__text{font-family:\"Figtree\", Sans-serif !important;}<\/style><h3 class=\"stk-block-heading__text\"><span style=\"color: var(--ast-global-color-3);\" class=\"stk-highlight\"><strong>Que resultados foram obtidos com a colite ulcerosa?<\/strong><\/span><\/h3><\/div>\n\n\n\n<div class=\"wp-block-stackable-columns stk-block-columns stk-block stk-af18160\" data-block-id=\"af18160\"><style>.stk-af18160 {margin-bottom:18px !important;}<\/style><div class=\"stk-row stk-inner-blocks stk-block-content stk-content-align stk-af18160-column\">\n<div class=\"wp-block-stackable-column stk-block-column stk-column stk-block stk-a54b1b5\" data-v=\"4\" data-block-id=\"a54b1b5\"><div class=\"stk-column-wrapper stk-block-column__content stk-container stk-a54b1b5-container stk--no-background stk--no-padding\"><div class=\"stk-block-content stk-inner-blocks stk-a54b1b5-inner-blocks\">\n<div class=\"wp-block-stackable-text stk-block-text stk-block stk-f91bd46\" data-block-id=\"f91bd46\"><style>.stk-f91bd46 .stk-block-text__text{font-family:\"Figtree\", Sans-serif !important;}<\/style><p class=\"stk-block-text__text\">No ensaio de fase 2, foi demonstrado que os doentes que receberam a subst\u00e2ncia ativa conseguiram alcan\u00e7ar a remiss\u00e3o m\u00e9dica de forma mais fi\u00e1vel do que os doentes do grupo do placebo. O grupo com testes gen\u00e9ticos previamente positivos tamb\u00e9m respondeu significativamente melhor \u00e0 subst\u00e2ncia ativa do que o grupo com resultados de testes negativos. O mesmo se aplica aos doentes que receberam tratamento pr\u00e9vio com produtos biol\u00f3gicos ou um tratamento dependente de ester\u00f3ides. Tamb\u00e9m eles podem alcan\u00e7ar a remiss\u00e3o com o anticorpo TL1A.<\/p><\/div>\n\n\n\n<p>Globalmente, pode concluir-se que o anticorpo TL1A tem um efeito positivo nas pessoas diagnosticadas com colite ulcerosa.<\/p>\n<\/div><\/div><\/div>\n\n\n\n<div class=\"wp-block-stackable-column stk-block-column stk-column stk-block stk-2e7483c\" data-v=\"4\" data-block-id=\"2e7483c\"><div class=\"stk-column-wrapper stk-block-column__content stk-container stk-2e7483c-container stk--no-background stk--no-padding\"><div class=\"stk-block-content stk-inner-blocks stk-2e7483c-inner-blocks\">\n<div class=\"wp-block-stackable-image alignfull stk-block-image stk-block stk-a434422\" data-block-id=\"a434422\"><figure><span class=\"stk-img-wrapper stk-image--shape-stretch\"><img loading=\"lazy\" decoding=\"async\" class=\"stk-img wp-image-4299\" src=\"https:\/\/cms.core-way.de\/wp-content\/uploads\/2025\/09\/50.png\" width=\"1366\" height=\"768\" alt=\"A figura mostra uma folha de teste para valores sangu\u00edneos. Nesta folha de teste encontram-se duas ampolas com amostras de sangue. A imagem simboliza os resultados que a subst\u00e2ncia ativa tulisocibart produziu em doentes com doen\u00e7a de Crohn e colite ulcerosa. Estes resultados s\u00e3o positivos.\" srcset=\"https:\/\/cms.core-way.de\/wp-content\/uploads\/2025\/09\/50.png 1366w, https:\/\/cms.core-way.de\/wp-content\/uploads\/2025\/09\/50-300x169.png 300w, https:\/\/cms.core-way.de\/wp-content\/uploads\/2025\/09\/50-1024x576.png 1024w, https:\/\/cms.core-way.de\/wp-content\/uploads\/2025\/09\/50-768x432.png 768w, https:\/\/cms.core-way.de\/wp-content\/uploads\/2025\/09\/50-480x270.png 480w, https:\/\/cms.core-way.de\/wp-content\/uploads\/2025\/09\/50-18x10.png 18w\" sizes=\"auto, (max-width: 1366px) 100vw, 1366px\" \/><\/span><\/figure><\/div>\n<\/div><\/div><\/div>\n<\/div><\/div>\n\n\n\n<div class=\"wp-block-stackable-heading stk-block-heading stk-block-heading--v2 stk-block stk-98dad5e\" id=\"strong-span-style-color-var-ast-global-color-3-class-stk-highlight-so-wurde-tulisokibart-bei-morbus-crohn-eingesetzt-span-strong\" data-block-id=\"98dad5e\"><h2 class=\"stk-block-heading__text\"><strong><span style=\"color: var(--ast-global-color-3);\" class=\"stk-highlight\">Como o Tulisokibart foi utilizado para a doen\u00e7a de Crohn<\/span><\/strong><\/h2><\/div>\n\n\n\n<div class=\"wp-block-stackable-text stk-block-text stk-block stk-056664b\" data-block-id=\"056664b\"><style>.stk-056664b {margin-bottom:19px !important;}<\/style><p class=\"stk-block-text__text\">Um estudo de fase 2a tamb\u00e9m investigou a rela\u00e7\u00e3o entre a doen\u00e7a de Crohn e a obten\u00e7\u00e3o de remiss\u00e3o com o novo anticorpo tulisokibart. Os doentes com doen\u00e7a de Crohn que participaram no estudo tinham em comum o facto de a progress\u00e3o da sua doen\u00e7a ter sido classificada como moderada a gravemente ativa e de terem sido, na sua maioria, tratados com novos medicamentos.<\/p><\/div>\n\n\n\n<div class=\"wp-block-stackable-heading stk-block-heading stk-block-heading--v2 stk-block stk-7e10c94\" id=\"span-style-color-var-ast-global-color-3-class-stk-highlight-strong-diese-ergebnisse-gab-es-bei-morbus-crohn-strong-span\" data-block-id=\"7e10c94\"><style>.stk-7e10c94 .stk-block-heading__text{font-family:\"Figtree\", Sans-serif !important;}<\/style><h3 class=\"stk-block-heading__text\"><span style=\"color: var(--ast-global-color-3);\" class=\"stk-highlight\"><strong>Estes foram os resultados para a doen\u00e7a de Crohn<\/strong><\/span><\/h3><\/div>\n\n\n\n<div class=\"wp-block-stackable-columns stk-block-columns stk-block stk-ce9d375\" data-block-id=\"ce9d375\"><style>.stk-ce9d375 {margin-bottom:19px !important;}<\/style><div class=\"stk-row stk-inner-blocks stk-block-content stk-content-align stk-ce9d375-column\">\n<div class=\"wp-block-stackable-column stk-block-column stk-column stk-block stk-30e5035\" data-v=\"4\" data-block-id=\"30e5035\"><div class=\"stk-column-wrapper stk-block-column__content stk-container stk-30e5035-container stk--no-background stk--no-padding\"><div class=\"stk-block-content stk-inner-blocks stk-30e5035-inner-blocks\">\n<div class=\"wp-block-stackable-text stk-block-text stk-block stk-f824fbf\" data-block-id=\"f824fbf\"><p class=\"stk-block-text__text\">No ensaio de fase 2a, no qual o efeito do anticorpo TL1A foi testado na doen\u00e7a de Crohn moderada a gravemente ativa, os doentes tamb\u00e9m conseguiram alcan\u00e7ar a remiss\u00e3o em compara\u00e7\u00e3o com o grupo do placebo. N\u00e3o importava se os doentes j\u00e1 tinham recebido tratamento ou n\u00e3o.<\/p><\/div>\n<\/div><\/div><\/div>\n\n\n\n<div class=\"wp-block-stackable-column stk-block-column stk-column stk-block stk-5e43ca0\" data-v=\"4\" data-block-id=\"5e43ca0\"><div class=\"stk-column-wrapper stk-block-column__content stk-container stk-5e43ca0-container stk--no-background stk--no-padding\"><div class=\"stk-block-content stk-inner-blocks stk-5e43ca0-inner-blocks\">\n<div class=\"wp-block-stackable-image stk-block-image stk-block stk-966785d\" data-block-id=\"966785d\"><figure><span class=\"stk-img-wrapper stk-image--shape-stretch\"><img loading=\"lazy\" decoding=\"async\" class=\"stk-img wp-image-4299\" src=\"https:\/\/cms.core-way.de\/wp-content\/uploads\/2025\/09\/50.png\" width=\"1366\" height=\"768\" alt=\"A figura mostra uma folha de teste na qual s\u00e3o registados os valores de teste do sangue. Nesta folha de teste h\u00e1 duas ampolas. Uma est\u00e1 cheia de sangue e a outra de um l\u00edquido amarelado. A que est\u00e1 cheia de sangue tem uma tampa cor-de-rosa e a outra tem uma tampa cor de laranja. Al\u00e9m disso, foram tamb\u00e9m recolhidas duas impress\u00f5es digitais com sangue do doente do lado direito. A imagem simboliza os resultados de um teste de despistagem de drogas.\" srcset=\"https:\/\/cms.core-way.de\/wp-content\/uploads\/2025\/09\/50.png 1366w, https:\/\/cms.core-way.de\/wp-content\/uploads\/2025\/09\/50-300x169.png 300w, https:\/\/cms.core-way.de\/wp-content\/uploads\/2025\/09\/50-1024x576.png 1024w, https:\/\/cms.core-way.de\/wp-content\/uploads\/2025\/09\/50-768x432.png 768w, https:\/\/cms.core-way.de\/wp-content\/uploads\/2025\/09\/50-480x270.png 480w, https:\/\/cms.core-way.de\/wp-content\/uploads\/2025\/09\/50-18x10.png 18w\" sizes=\"auto, (max-width: 1366px) 100vw, 1366px\" \/><\/span><\/figure><\/div>\n<\/div><\/div><\/div>\n<\/div><\/div>\n\n\n\n<div class=\"wp-block-stackable-heading stk-block-heading stk-block-heading--v2 stk-block stk-1636143\" id=\"span-style-color-var-ast-global-color-3-class-stk-highlight-strong-ausblick-fur-die-zukunft-strong-span\" data-block-id=\"1636143\"><style>.stk-1636143 .stk-block-heading__text{font-family:\"Figtree\", Sans-serif !important;}<\/style><h2 class=\"stk-block-heading__text\"><span style=\"color: var(--ast-global-color-3);\" class=\"stk-highlight\"> <strong>Perspectivas para o futuro<\/strong><\/span><\/h2><\/div>\n\n\n\n<div class=\"wp-block-stackable-text stk-block-text stk-block stk-7848aeb\" data-block-id=\"7848aeb\"><style>.stk-7848aeb {margin-bottom:19px !important;}.stk-7848aeb .stk-block-text__text{font-family:\"Figtree\", Sans-serif !important;}<\/style><p class=\"stk-block-text__text\">Os estudos atualmente em curso examinar\u00e3o o comportamento do anticorpo TL1A durante um per\u00edodo de tempo mais longo e se este pode, por conseguinte, contribuir para manter a remiss\u00e3o. Atualmente, n\u00e3o existem dados que comprovem se a subst\u00e2ncia ativa tamb\u00e9m \u00e9 eficaz a longo prazo na doen\u00e7a de Crohn e na colite ulcerosa.<\/p><\/div>\n\n\n\n<div class=\"wp-block-stackable-columns stk-block-columns stk-block stk-d9ecb93 stk-block-background\" data-block-id=\"d9ecb93\"><style>.stk-d9ecb93 {background-color:var(--ast-global-color-2) !important;}.stk-d9ecb93:before{background-color:var(--ast-global-color-2) !important;}<\/style><div class=\"stk-row stk-inner-blocks stk-block-content stk-content-align stk-d9ecb93-column\">\n<div class=\"wp-block-stackable-column stk-block-column stk-column stk-block stk-25432c5\" data-v=\"4\" data-block-id=\"25432c5\"><div class=\"stk-column-wrapper stk-block-column__content stk-container stk-25432c5-container stk--no-background stk--no-padding\"><div class=\"stk-block-content stk-inner-blocks stk-25432c5-inner-blocks\">\n<div class=\"wp-block-stackable-heading stk-block-heading stk-block-heading--v2 stk-block stk-e28265b stk-block-background\" id=\"quick-facts\" data-block-id=\"e28265b\"><style>.stk-e28265b {background-color:var(--ast-global-color-2) !important;}.stk-e28265b:before{background-color:var(--ast-global-color-2) !important;}<\/style><h2 class=\"stk-block-heading__text\">Factos r\u00e1pidos:<\/h2><\/div>\n\n\n\n<ul class=\"wp-block-list\">\n<li>A subst\u00e2ncia ativa tulisokibart oferece uma nova esperan\u00e7a aos doentes com colite ulcerosa moderada a grave e doen\u00e7a de Crohn moderada a grave.<\/li>\n\n\n\n<li>Nos estudos m\u00e9dicos apresentados, a remiss\u00e3o foi alcan\u00e7ada tanto na colite ulcerosa como na doen\u00e7a de Crohn, mesmo que outras terapias tivessem falhado.<\/li>\n\n\n\n<li>Os novos testes gen\u00e9ticos utilizados s\u00e3o mais um passo em dire\u00e7\u00e3o ao tratamento individualizado da DII.<\/li>\n<\/ul>\n<\/div><\/div><\/div>\n<\/div><\/div>\n\n\n\n<details class=\"wp-block-stackable-accordion stk-block-accordion stk-inner-blocks stk-block-content stk-block stk-3a889f6 is-style-default\" data-block-id=\"3a889f6\">\n<summary class=\"wp-block-stackable-column stk-block-column stk-column stk-block stk-f479e95 stk--container-small stk-block-accordion__heading\" data-v=\"4\" data-block-id=\"f479e95\"><style>.stk-f479e95 {border-top-left-radius:0px !important;border-top-right-radius:0px !important;border-bottom-right-radius:0px !important;border-bottom-left-radius:0px !important;overflow:hidden !important;box-shadow:none !important;border-color:var(--ast-global-color-6) !important;}.stk-f479e95-container{background-color:var(--ast-global-color-6) !important;}.stk-f479e95-container:before{background-color:var(--ast-global-color-6) !important;}<\/style><div class=\"stk-column-wrapper stk-block-column__content stk-container stk-f479e95-container stk-hover-parent\"><div class=\"stk-block-content stk-inner-blocks stk-f479e95-inner-blocks\">\n<div class=\"wp-block-stackable-icon-label stk-block-icon-label stk-block stk-078fb99\" data-block-id=\"078fb99\"><div class=\"stk-row stk-inner-blocks stk-block-content\">\n<div class=\"wp-block-stackable-heading stk-block-heading stk-block-heading--v2 stk-block stk-a15b6d4 stk-block-background\" id=\"quellen\" data-block-id=\"a15b6d4\"><style>.stk-a15b6d4 {background-color:var(--ast-global-color-6) !important;border-style:solid !important;border-top-width:0px !important;border-right-width:0px !important;border-bottom-width:0px !important;border-left-width:0px !important;}.stk-a15b6d4:before{background-color:var(--ast-global-color-6) !important;}.stk-a15b6d4 .stk-block-heading__text{font-family:\"Figtree\", Sans-serif !important;}<\/style><h4 class=\"stk-block-heading__text\">Fontes<\/h4><\/div>\n\n\n\n<div class=\"wp-block-stackable-icon stk-block-icon stk-block stk-d17f4a5\" data-block-id=\"d17f4a5\"><style>.stk-d17f4a5 {border-top-width:0px !important;border-right-width:0px !important;border-bottom-width:0px !important;border-left-width:0px !important;}<\/style><span class=\"stk--svg-wrapper\"><div class=\"stk--inner-svg\"><svg style=\"height:0;width:0\"><defs><lineargradient id=\"linear-gradient-d17f4a5\" x1=\"0\" x2=\"100%\" y1=\"0\" y2=\"0\"><stop offset=\"0%\" style=\"stop-opacity:1;stop-color:var(--linear-gradient-d-17-f-4-a-5-color-1)\"><\/stop><stop offset=\"100%\" style=\"stop-opacity:1;stop-color:var(--linear-gradient-d-17-f-4-a-5-color-2)\"><\/stop><\/lineargradient><\/defs><\/svg><svg data-prefix=\"fas\" data-icon=\"chevron-down\" class=\"svg-inline--fa fa-chevron-down fa-w-14\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" viewbox=\"0 0 448 512\" aria-hidden=\"true\" width=\"32\" height=\"32\"><path fill=\"currentColor\" d=\"M207.029 381.476L12.686 187.132c-9.373-9.373-9.373-24.569 0-33.941l22.667-22.667c9.357-9.357 24.522-9.375 33.901-.04L224 284.505l154.745-154.021c9.379-9.335 24.544-9.317 33.901.04l22.667 22.667c9.373 9.373 9.373 24.569 0 33.941L240.971 381.476c-9.373 9.372-24.569 9.372-33.942 0z\"><\/path><\/svg><\/div><\/span><\/div>\n<\/div><\/div>\n<\/div><\/div><\/summary>\n\n\n\n<div class=\"wp-block-stackable-column stk-block-column stk-column stk-block stk-9e131e1 stk-block-accordion__content\" data-v=\"4\" data-block-id=\"9e131e1\"><div class=\"stk-column-wrapper stk-block-column__content stk-container stk-9e131e1-container stk--no-background stk--no-padding\"><div class=\"stk-block-content stk-inner-blocks stk-9e131e1-inner-blocks\">\n<div class=\"wp-block-stackable-text stk-block-text stk-block stk-7f61001\" data-block-id=\"7f61001\"><p class=\"stk-block-text__text\">Funda\u00e7\u00e3o Falk e. V. (2025). Estudo de fase II com o anticorpo monoclonal TL1A tulisokibart na colite ulcerosa. <em>Falk Gastro Review - Science compact<\/em>. Obtido em 24 de setembro de 2025, de <a href=\"https:\/\/falkfoundation.org\/de\/fgr\/detail\/phase-ii-studie-mit-monoklonalem-tl1a-antikoerper-tulisokibart-bei-colitis-ulcerosa?utm_source=chatgpt.com\">https:\/\/falkfoundation.org\/de\/fgr\/detail\/phase-ii-studie-mit-monoklonalem-tl1a-antikoerper-tulisokibart-bei-colitis-ulcerosa<\/a> <a href=\"https:\/\/falkfoundation.org\/de\/fgr\/detail\/phase-ii-studie-mit-monoklonalem-tl1a-antikoerper-tulisokibart-bei-colitis-ulcerosa\" target=\"_blank\" rel=\"noreferrer noopener\">Funda\u00e7\u00e3o Falk<\/a><\/p><\/div>\n\n\n\n<p>Althaus, D., &amp; Hr\u00faz, P. (2025, 9 de setembro). Nova abordagem terap\u00eautica para a doen\u00e7a inflamat\u00f3ria cr\u00f3nica do intestino - TL1A. <em>Gastroenterologia Su\u00ed\u00e7a, 6<\/em>, 112-114. <a>https:\/\/doi.org\/10.1007\/s43472-025-00176-7<\/a> <a href=\"https:\/\/link.springer.com\/article\/10.1007\/s43472-025-00176-7\" target=\"_blank\" rel=\"noreferrer noopener\">SpringerLink<\/a><\/p>\n\n\n\n<p>Feagan, B. G., Sands, B. E., Siegel, C. A., <em>et al.<\/em> (2025). Seguran\u00e7a e efic\u00e1cia do anticorpo monoclonal anti-TL1A tulisokibart para a doen\u00e7a de Crohn: um ensaio de indu\u00e7\u00e3o de fase 2a. <em>The Lancet Gastroenterology &amp; Hepatology, 10<\/em>(8), 715-725. <a>https:\/\/doi.org\/10.1016\/S2468-1253(25)00071-8<\/a> <a href=\"https:\/\/www.thelancet.com\/cms\/10.1016\/S2468-1253%2825%2900071-8\/attachment\/25d0d778-ef84-44fe-992a-84fdafa867b9\/mmc1.pdf?utm_source=chatgpt.com\" target=\"_blank\" rel=\"noreferrer noopener\">The Lancet+1<\/a><\/p>\n\n\n\n<p>Zinkant, K. (2023, 24 de maio). Descanso no intestino: Nova terapia para a doen\u00e7a de Crohn e colite ulcerosa. <em>Revis\u00e3o das farm\u00e1cias<\/em>. <a href=\"https:\/\/www.apotheken-umschau.de\/krankheiten-symptome\/magen-und-darmerkrankungen\/endlich-ruhe-im-darm-neue-therapie-bei-morbus-crohn-und-colitis-ulcerosa-963957.html?utm_source=chatgpt.com\">https:\/\/www.apotheken-umschau.de\/krankheiten-symptome\/magen-und-darmerkrankungen\/endlich-ruhe-im-darm-neue-therapie-bei-morbus-crohn-und-colitis-ulcerosa-963957.html<\/a> <a href=\"https:\/\/www.apotheken-umschau.de\/krankheiten-symptome\/magen-und-darmerkrankungen\/endlich-ruhe-im-darm-neue-therapie-bei-morbus-crohn-und-colitis-ulcerosa-963957.html\" target=\"_blank\" rel=\"noreferrer noopener\">Revis\u00e3o das farm\u00e1cias<\/a><\/p>\n\n\n\n<p>Antwerpes, F. (2025, 16 de setembro). Tulisokibart. <em>DocCheck Flexicon<\/em>. Obtido em 24 de setembro de 2025, de <a href=\"https:\/\/flexikon.doccheck.com\/de\/Tulisokibart?utm_source=chatgpt.com\">https:\/\/flexikon.doccheck.com\/de\/Tulisokibart<\/a> <a href=\"https:\/\/flexikon.doccheck.com\/de\/Tulisokibart\" target=\"_blank\" rel=\"noreferrer noopener\">DocCheck Flexicon<\/a><\/p>\n\n\n\n<p>Abels, B., Leyrer, R., Antwerpes, F., Meiners, J., Springer, F., <em>et al.<\/em> (2024, 21 de mar\u00e7o). Citocina. <em>DocCheck Flexicon<\/em>. Obtido em 24 de setembro de 2025, de <a href=\"https:\/\/flexikon.doccheck.com\/de\/Zytokin?utm_source=chatgpt.com\">https:\/\/flexikon.doccheck.com\/de\/Zytokin<\/a> <a href=\"https:\/\/flexikon.doccheck.com\/de\/Zytokin\" target=\"_blank\" rel=\"noreferrer noopener\">DocCheck Flexicon<\/a><\/p>\n\n\n\n<p>Wodarz, G., Antwerpes, F. (2024, 21 de mar\u00e7o). Recetor de morte 3. <em>DocCheck Flexicon<\/em>. Obtido em 24 de setembro de 2025, de <a href=\"https:\/\/flexikon.doccheck.com\/de\/Death-Rezeptor_3?utm_source=chatgpt.com\">https:\/\/flexikon.doccheck.com\/de\/Death-Rezeptor_3<\/a> <a href=\"https:\/\/flexikon.doccheck.com\/de\/Death-Rezeptor_3\" target=\"_blank\" rel=\"noreferrer noopener\">DocCheck Flexicon<\/a><\/p>\n\n\n\n<p>Wodarz, G., Antwerpes, F., Schuff, M., Reh, F., &amp; Schwarzlm\u00fcller, P. (2025, 16 de setembro). TL1A. <em>DocCheck Flexicon<\/em>. Obtido em 24 de setembro de 2025, de <a href=\"https:\/\/flexikon.doccheck.com\/de\/TL1A?utm_source=chatgpt.com\">https:\/\/flexikon.doccheck.com\/de\/TL1A<\/a> <a href=\"https:\/\/flexikon.doccheck.com\/de\/TL1A\" target=\"_blank\" rel=\"noreferrer noopener\">DocCheck Flexicon<\/a><\/p>\n\n\n\n<p>Sands, B. E., Feagan, B. G., Peyrin-Biroulet, L., Danese, S., Rubin, D. T., Laurent, O., Luo, A., Nguyen, D. D., Lu, J., Yen, M., Leszczyszyn, J., Kempi\u0144ski, R., McGovern, D. P. B., Ma, C., Ritter, T. E., Targan, S., &amp; Grupo de Estudo ARTEMIS-UC. (2024). Ensaio de fase 2 do anticorpo monoclonal anti-TL1A tulisokibart para colite ulcerosa. <em>The New England Journal of Medicine, 391<\/em>(12), 1119-1129. <a>https:\/\/doi.org\/10.1056\/NEJMoa2314076<\/a> <a href=\"https:\/\/www.nejm.org\/doi\/pdf\/10.1056\/NEJMoa2314076?utm_source=chatgpt.com\" target=\"_blank\" rel=\"noreferrer noopener\">Jornal de Medicina de Nova Inglaterra<\/a><\/p>\n\n\n\n<p>MedMedia (ed.). (2025). Uma nova abordagem promissora para o tratamento da doen\u00e7a de Crohn moderada a grave (ECCO 2025). <em>congresso-x-imprensa<\/em>. Obtido em 24 de setembro de 2025, de <a href=\"https:\/\/www.medmedia.at\/congress-x-press\/ecco\/ein-vielversprechender-neuer-ansatz-zur-therapie-eines-moderaten-bis-schweren-morbus-crohn?utm_source=chatgpt.com\">https:\/\/www.medmedia.at\/congress-x-press\/ecco\/ein-vielversprechender-neuer-ansatz-zur-therapie-eines-moderaten-bis-schweren-morbus-crohn<\/a><\/p>\n<\/div><\/div><\/div>\n<\/details>\n\n\n\n<div class=\"wp-block-stackable-heading stk-block-heading stk-block-heading--v2 stk-block stk-e37d4b7\" id=\"span-style-color-var-ast-global-color-3-class-stk-highlight-weitere-interessante-artikel-span\" data-block-id=\"e37d4b7\"><style>.stk-e37d4b7 .stk-block-heading__text{font-family:\"Figtree\", Sans-serif !important;}<\/style><h2 class=\"stk-block-heading__text\"><span style=\"color: var(--ast-global-color-3);\" class=\"stk-highlight\">Mais artigos interessantes<\/span><\/h2><\/div>\n\n\n\n<div class=\"wp-block-stackable-feature-grid alignwide stk-block-feature-grid stk-block-columns stk-block stk-50fc686 is-style-default\" data-block-id=\"50fc686\"><div class=\"stk-row stk-inner-blocks has-text-align-center stk-block-content stk-content-align stk-50fc686-column alignwide\">\n<div class=\"wp-block-stackable-column stk-block-column stk-column stk-block stk-3e980d6\" data-v=\"4\" data-block-id=\"3e980d6\"><div class=\"stk-column-wrapper stk-block-column__content stk-container stk-3e980d6-container stk-hover-parent\"><div class=\"stk-block-content stk-inner-blocks stk-3e980d6-inner-blocks\">\n<div class=\"wp-block-stackable-image stk-block-image stk-block stk-4c33f1c\" data-block-id=\"4c33f1c\"><figure><span class=\"stk-img-wrapper stk-image--shape-stretch\"><img loading=\"lazy\" decoding=\"async\" class=\"stk-img wp-image-3396\" src=\"https:\/\/cms.core-way.de\/wp-content\/uploads\/2024\/06\/Bilder-Blogbeitraege-4.png\" width=\"1366\" height=\"768\" srcset=\"https:\/\/cms.core-way.de\/wp-content\/uploads\/2024\/06\/Bilder-Blogbeitraege-4.png 1366w, https:\/\/cms.core-way.de\/wp-content\/uploads\/2024\/06\/Bilder-Blogbeitraege-4-300x169.png 300w, https:\/\/cms.core-way.de\/wp-content\/uploads\/2024\/06\/Bilder-Blogbeitraege-4-1024x576.png 1024w, https:\/\/cms.core-way.de\/wp-content\/uploads\/2024\/06\/Bilder-Blogbeitraege-4-768x432.png 768w, https:\/\/cms.core-way.de\/wp-content\/uploads\/2024\/06\/Bilder-Blogbeitraege-4-480x270.png 480w, https:\/\/cms.core-way.de\/wp-content\/uploads\/2024\/06\/Bilder-Blogbeitraege-4-18x10.png 18w\" sizes=\"auto, (max-width: 1366px) 100vw, 1366px\" \/><\/span><\/figure><\/div>\n\n\n\n<div class=\"wp-block-stackable-text stk-block-text stk-block stk-b28ef1b\" id=\"schwangerschaft-und-c-ed\" data-block-id=\"b28ef1b\"><style>.stk-b28ef1b .stk-block-text__text{font-size:20px !important;}@media screen and (max-width: 1023px){.stk-b28ef1b .stk-block-text__text{font-size:20px !important;}}<\/style><p class=\"stk-block-text__text\"><strong>Terapia com c\u00e9lulas estaminais mesenquimais para a DII: uma nova esperan\u00e7a?<\/strong><\/p><\/div>\n\n\n\n<div class=\"wp-block-stackable-text stk-block-text stk-block stk-c3b2eb4\" data-block-id=\"c3b2eb4\"><p class=\"stk-block-text__text\">A terapia com MSC oferece uma nova e prometedora op\u00e7\u00e3o de tratamento para a DII. Mas como \u00e9 que a terapia funciona, at\u00e9 que ponto a investiga\u00e7\u00e3o progrediu e o que significa para as pessoas afectadas?<\/p><\/div>\n\n\n\n<div class=\"wp-block-stackable-button-group stk-block-button-group stk-block stk-9dba7e2\" data-block-id=\"9dba7e2\"><div class=\"stk-row stk-inner-blocks stk-block-content stk-button-group\">\n<div class=\"wp-block-stackable-button stk-block-button stk-block stk-3f2b27d\" data-block-id=\"3f2b27d\"><style>.stk-3f2b27d .stk-button{background:var(--ast-global-color-0) !important;}.stk-3f2b27d .stk-button__inner-text{color:var(--ast-global-color-7) !important;}<\/style><a class=\"stk-link stk-button stk--hover-effect-darken\" href=\"https:\/\/cms.core-way.de\/pt\/terapia-com-celulas-estaminais-mesenquimais-para-a-ced-um-olhar-para-o-futuro\/\"><span class=\"has-text-color stk-button__inner-text\">Saiba mais<\/span><\/a><\/div>\n<\/div><\/div>\n<\/div><\/div><\/div>\n\n\n\n<div class=\"wp-block-stackable-column stk-block-column stk-column stk-block stk-2e5b5ab\" data-v=\"4\" data-block-id=\"2e5b5ab\"><div class=\"stk-column-wrapper stk-block-column__content stk-container stk-2e5b5ab-container stk-hover-parent\"><div class=\"stk-block-content stk-inner-blocks stk-2e5b5ab-inner-blocks\">\n<div class=\"wp-block-stackable-image stk-block-image stk-block stk-554a541\" data-block-id=\"554a541\"><figure><span class=\"stk-img-wrapper stk-image--shape-stretch\"><img loading=\"lazy\" decoding=\"async\" class=\"stk-img wp-image-3392\" src=\"https:\/\/cms.core-way.de\/wp-content\/uploads\/2025\/02\/Bilder-Blogbeitraege-3.png\" width=\"1366\" height=\"768\" srcset=\"https:\/\/cms.core-way.de\/wp-content\/uploads\/2025\/02\/Bilder-Blogbeitraege-3.png 1366w, https:\/\/cms.core-way.de\/wp-content\/uploads\/2025\/02\/Bilder-Blogbeitraege-3-300x169.png 300w, https:\/\/cms.core-way.de\/wp-content\/uploads\/2025\/02\/Bilder-Blogbeitraege-3-1024x576.png 1024w, https:\/\/cms.core-way.de\/wp-content\/uploads\/2025\/02\/Bilder-Blogbeitraege-3-768x432.png 768w, https:\/\/cms.core-way.de\/wp-content\/uploads\/2025\/02\/Bilder-Blogbeitraege-3-480x270.png 480w, https:\/\/cms.core-way.de\/wp-content\/uploads\/2025\/02\/Bilder-Blogbeitraege-3-18x10.png 18w\" sizes=\"auto, (max-width: 1366px) 100vw, 1366px\" \/><\/span><\/figure><\/div>\n\n\n\n<div class=\"wp-block-stackable-text stk-block-text stk-block stk-f864b66\" id=\"komplementare-therapien\" data-block-id=\"f864b66\"><style>.stk-f864b66 .stk-block-text__text{font-size:20px !important;}@media screen and (max-width: 1023px){.stk-f864b66 .stk-block-text__text{font-size:20px !important;}}<\/style><p class=\"stk-block-text__text\"><strong>O microbioma \u00e9 a chave? - Nova terapia para a doen\u00e7a de Crohn<\/strong><\/p><\/div>\n\n\n\n<div class=\"wp-block-stackable-text stk-block-text stk-block stk-2f7230b\" data-block-id=\"2f7230b\"><p class=\"stk-block-text__text\">A doen\u00e7a de Crohn \u00e9 uma doen\u00e7a inflamat\u00f3ria intestinal cr\u00f3nica (DII) que afecta a vida de milh\u00f5es de pessoas em todo o mundo. Uma terapia comprovada \u00e9 a nutri\u00e7\u00e3o enteral exclusiva (NEE) - uma dieta l\u00edquida especial que os doentes consomem durante seis a oito semanas em vez de alimentos s\u00f3lidos.&nbsp;<\/p><\/div>\n\n\n\n<div class=\"wp-block-stackable-button-group stk-block-button-group stk-block stk-b5a6885\" data-block-id=\"b5a6885\"><div class=\"stk-row stk-inner-blocks stk-block-content stk-button-group\">\n<div class=\"wp-block-stackable-button stk-block-button stk-block stk-f91979c\" data-block-id=\"f91979c\"><style>.stk-f91979c .stk-button{background:var(--ast-global-color-0) !important;}.stk-f91979c .stk-button__inner-text{color:var(--ast-global-color-7) !important;}<\/style><a class=\"stk-link stk-button stk--hover-effect-darken\" href=\"https:\/\/cms.core-way.de\/pt\/estudo-do-microbioma\/\"><span class=\"has-text-color stk-button__inner-text\">Saiba mais<\/span><\/a><\/div>\n<\/div><\/div>\n<\/div><\/div><\/div>\n\n\n\n<div class=\"wp-block-stackable-column stk-block-column stk-column stk-block stk-56de09b\" data-v=\"4\" data-block-id=\"56de09b\"><div class=\"stk-column-wrapper stk-block-column__content stk-container stk-56de09b-container stk-hover-parent\"><div class=\"stk-block-content stk-inner-blocks stk-56de09b-inner-blocks\">\n<div class=\"wp-block-stackable-image stk-block-image stk-block stk-92167d0\" data-block-id=\"92167d0\"><figure><span class=\"stk-img-wrapper stk-image--shape-stretch\"><img loading=\"lazy\" decoding=\"async\" class=\"stk-img wp-image-4129\" src=\"https:\/\/cms.core-way.de\/wp-content\/uploads\/2025\/09\/Bilder-Blogbeitraege-16.png\" width=\"1366\" height=\"768\" srcset=\"https:\/\/cms.core-way.de\/wp-content\/uploads\/2025\/09\/Bilder-Blogbeitraege-16.png 1366w, https:\/\/cms.core-way.de\/wp-content\/uploads\/2025\/09\/Bilder-Blogbeitraege-16-300x169.png 300w, https:\/\/cms.core-way.de\/wp-content\/uploads\/2025\/09\/Bilder-Blogbeitraege-16-1024x576.png 1024w, https:\/\/cms.core-way.de\/wp-content\/uploads\/2025\/09\/Bilder-Blogbeitraege-16-768x432.png 768w, https:\/\/cms.core-way.de\/wp-content\/uploads\/2025\/09\/Bilder-Blogbeitraege-16-480x270.png 480w, https:\/\/cms.core-way.de\/wp-content\/uploads\/2025\/09\/Bilder-Blogbeitraege-16-18x10.png 18w\" sizes=\"auto, (max-width: 1366px) 100vw, 1366px\" \/><\/span><\/figure><\/div>\n\n\n\n<div class=\"wp-block-stackable-text stk-block-text stk-block stk-0d4dfda\" id=\"strong-sepsis-bei-ced-was-du-wissen-solltest-strong\" data-block-id=\"0d4dfda\"><style>.stk-0d4dfda .stk-block-text__text{font-size:20px !important;}@media screen and (max-width: 1023px){.stk-0d4dfda .stk-block-text__text{font-size:20px !important;}}<\/style><p class=\"stk-block-text__text\"><strong>Sepsis na DII: o que deve saber<\/strong><\/p><\/div>\n\n\n\n<div class=\"wp-block-stackable-text stk-block-text stk-block stk-762284a\" data-block-id=\"762284a\"><p class=\"stk-block-text__text\">Para as pessoas com doen\u00e7a de Crohn ou colite ulcerosa, o foco \u00e9 frequentemente a vida quotidiana com diarreia, dor ou fadiga. No entanto, tamb\u00e9m podem ocorrer complica\u00e7\u00f5es graves - incluindo septicemia (muitas vezes tamb\u00e9m conhecida como envenenamento do sangue ou infe\u00e7\u00e3o da corrente sangu\u00ednea).<strong>&nbsp;<\/strong><\/p><\/div>\n\n\n\n<div class=\"wp-block-stackable-button-group stk-block-button-group stk-block stk-e32dc44\" data-block-id=\"e32dc44\"><div class=\"stk-row stk-inner-blocks stk-block-content stk-button-group\">\n<div class=\"wp-block-stackable-button stk-block-button stk-block stk-4a737fc\" data-block-id=\"4a737fc\"><style>.stk-4a737fc .stk-button{background:var(--ast-global-color-0) !important;}.stk-4a737fc .stk-button__inner-text{color:var(--ast-global-color-7) !important;}<\/style><a class=\"stk-link stk-button stk--hover-effect-darken\" href=\"https:\/\/cms.core-way.de\/pt\/sepsis-com-ced\/\"><span class=\"has-text-color stk-button__inner-text\">Saiba mais<\/span><\/a><\/div>\n<\/div><\/div>\n<\/div><\/div><\/div>\n<\/div><\/div>\n\n\n\n<div class=\"wp-block-stackable-heading stk-block-heading stk-block-heading--v2 stk-block stk-31d304a\" data-block-id=\"31d304a\"><h2 class=\"stk-block-heading__text\"><\/h2><\/div>","protected":false},"excerpt":{"rendered":"<p>O princ\u00edpio ativo Tulisokibart: Esperan\u00e7a para os doentes com DII? A doen\u00e7a de Crohn e a colite ulcerosa afectam todos os doentes e todos os [...]<\/p>","protected":false},"author":10,"featured_media":4297,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_coblocks_attr":"","_coblocks_dimensions":"","_coblocks_responsive_height":"","_coblocks_accordion_ie_support":"","inline_featured_image":false,"_uag_custom_page_level_css":"","site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"disabled","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"_glsr_average":0,"_glsr_ranking":0,"_glsr_reviews":0,"footnotes":""},"categories":[12],"tags":[270,345,383,348,19,62,263,122,128,54,163,386,385],"class_list":["post-4292","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-ced-wissen-forschung","tag-behandlung-von-ced","tag-behandlung-von-colitis-ulcerosa","tag-behandlung-von-morbus-crohn","tag-behandlungsmoeglichkeiten","tag-ced","tag-chronisch-entzuendliche-darmerkrankungen","tag-colitis-ulceroa","tag-ibd","tag-morbus-crohn","tag-therapie","tag-treatment","tag-tulisokibart","tag-wirkstoff"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Der Wirkstoff Tulisokibart: Eine Hoffnung f\u00fcr Patient:innen mit CED? - coreway<\/title>\n<meta name=\"description\" content=\"Der Wirkstoff Tulisokibart konnte in Studien, Patient:innen mit chronisch-entz\u00fcndlichen Darmerkrankungen, helfen. Das ist der aktuelle Stand\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cms.core-way.de\/pt\/o-ingrediente-ativo-tulisokibart-uma-esperanca-para-os-doentes-com-ced\/\" \/>\n<meta property=\"og:locale\" content=\"pt_PT\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Der Wirkstoff Tulisokibart: Eine Hoffnung f\u00fcr Patient:innen mit CED? - coreway\" \/>\n<meta property=\"og:description\" content=\"Der Wirkstoff Tulisokibart konnte in Studien, Patient:innen mit chronisch-entz\u00fcndlichen Darmerkrankungen, helfen. Das ist der aktuelle Stand\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cms.core-way.de\/pt\/o-ingrediente-ativo-tulisokibart-uma-esperanca-para-os-doentes-com-ced\/\" \/>\n<meta property=\"og:site_name\" content=\"coreway\" \/>\n<meta property=\"article:published_time\" content=\"2025-09-29T14:47:14+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-09-29T14:47:20+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cms.core-way.de\/wp-content\/uploads\/2025\/09\/Bilder-Blogbeitraege-5.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1366\" \/>\n\t<meta property=\"og:image:height\" content=\"768\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Viktoria Endres\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Viktoria Endres\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tempo estimado de leitura\" \/>\n\t<meta name=\"twitter:data2\" content=\"8 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/cms.core-way.de\\\/der-wirkstoff-tulisokibart-eine-hoffnung-fuer-patientinnen-mit-ced\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/cms.core-way.de\\\/der-wirkstoff-tulisokibart-eine-hoffnung-fuer-patientinnen-mit-ced\\\/\"},\"author\":{\"name\":\"Viktoria Endres\",\"@id\":\"https:\\\/\\\/cms.core-way.de\\\/#\\\/schema\\\/person\\\/c3801c6b8c6c5095157d831a44019e1f\"},\"headline\":\"Der Wirkstoff Tulisokibart: Eine Hoffnung f\u00fcr Patient:innen mit CED?\",\"datePublished\":\"2025-09-29T14:47:14+00:00\",\"dateModified\":\"2025-09-29T14:47:20+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/cms.core-way.de\\\/der-wirkstoff-tulisokibart-eine-hoffnung-fuer-patientinnen-mit-ced\\\/\"},\"wordCount\":1255,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/cms.core-way.de\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/cms.core-way.de\\\/der-wirkstoff-tulisokibart-eine-hoffnung-fuer-patientinnen-mit-ced\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cms.core-way.de\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/Bilder-Blogbeitraege-5.png\",\"keywords\":[\"Behandlung von CED\",\"Behandlung von Colitis ulcerosa\",\"Behandlung von Morbus Crohn\",\"Behandlungsm\u00f6glichkeiten\",\"CED\",\"chronisch-entz\u00fcndliche Darmerkrankungen\",\"Colitis ulceroa\",\"IBD\",\"Morbus Crohn\",\"Therapie\",\"Treatment\",\"Tulisokibart\",\"Wirkstoff\"],\"articleSection\":[\"CED-Wissen &amp; Forschung: Diagnose, Behandlung &amp; Therapien\"],\"inLanguage\":\"pt-PT\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/cms.core-way.de\\\/der-wirkstoff-tulisokibart-eine-hoffnung-fuer-patientinnen-mit-ced\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/cms.core-way.de\\\/der-wirkstoff-tulisokibart-eine-hoffnung-fuer-patientinnen-mit-ced\\\/\",\"url\":\"https:\\\/\\\/cms.core-way.de\\\/der-wirkstoff-tulisokibart-eine-hoffnung-fuer-patientinnen-mit-ced\\\/\",\"name\":\"Der Wirkstoff Tulisokibart: Eine Hoffnung f\u00fcr Patient:innen mit CED? - coreway\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/cms.core-way.de\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/cms.core-way.de\\\/der-wirkstoff-tulisokibart-eine-hoffnung-fuer-patientinnen-mit-ced\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/cms.core-way.de\\\/der-wirkstoff-tulisokibart-eine-hoffnung-fuer-patientinnen-mit-ced\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cms.core-way.de\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/Bilder-Blogbeitraege-5.png\",\"datePublished\":\"2025-09-29T14:47:14+00:00\",\"dateModified\":\"2025-09-29T14:47:20+00:00\",\"description\":\"Der Wirkstoff Tulisokibart konnte in Studien, Patient:innen mit chronisch-entz\u00fcndlichen Darmerkrankungen, helfen. Das ist der aktuelle Stand\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/cms.core-way.de\\\/der-wirkstoff-tulisokibart-eine-hoffnung-fuer-patientinnen-mit-ced\\\/#breadcrumb\"},\"inLanguage\":\"pt-PT\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/cms.core-way.de\\\/der-wirkstoff-tulisokibart-eine-hoffnung-fuer-patientinnen-mit-ced\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"pt-PT\",\"@id\":\"https:\\\/\\\/cms.core-way.de\\\/der-wirkstoff-tulisokibart-eine-hoffnung-fuer-patientinnen-mit-ced\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cms.core-way.de\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/Bilder-Blogbeitraege-5.png\",\"contentUrl\":\"https:\\\/\\\/cms.core-way.de\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/Bilder-Blogbeitraege-5.png\",\"width\":1366,\"height\":768},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/cms.core-way.de\\\/der-wirkstoff-tulisokibart-eine-hoffnung-fuer-patientinnen-mit-ced\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/cms.core-way.de\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Der Wirkstoff Tulisokibart: Eine Hoffnung f\u00fcr Patient:innen mit CED?\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/cms.core-way.de\\\/#website\",\"url\":\"https:\\\/\\\/cms.core-way.de\\\/\",\"name\":\"coreway\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/cms.core-way.de\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/cms.core-way.de\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"pt-PT\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/cms.core-way.de\\\/#organization\",\"name\":\"coreway\",\"url\":\"https:\\\/\\\/cms.core-way.de\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"pt-PT\",\"@id\":\"https:\\\/\\\/cms.core-way.de\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/cms.core-way.de\\\/wp-content\\\/uploads\\\/2023\\\/09\\\/Black-And-White-Aesthetic-Minimalist-Modern-Simple-Typography-Coconut-Cosmetics-Logo-5.png\",\"contentUrl\":\"https:\\\/\\\/cms.core-way.de\\\/wp-content\\\/uploads\\\/2023\\\/09\\\/Black-And-White-Aesthetic-Minimalist-Modern-Simple-Typography-Coconut-Cosmetics-Logo-5.png\",\"width\":500,\"height\":500,\"caption\":\"coreway\"},\"image\":{\"@id\":\"https:\\\/\\\/cms.core-way.de\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.instagram.com\\\/core.way\\\/\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/92284357\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/cms.core-way.de\\\/#\\\/schema\\\/person\\\/c3801c6b8c6c5095157d831a44019e1f\",\"name\":\"Viktoria Endres\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"pt-PT\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/2d515c89c7924f2d3779db2c7424dc10b0cefc7048bcc003cc3b5e929e7e32dc?s=96&#038;d=mm&#038;r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/2d515c89c7924f2d3779db2c7424dc10b0cefc7048bcc003cc3b5e929e7e32dc?s=96&#038;d=mm&#038;r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/2d515c89c7924f2d3779db2c7424dc10b0cefc7048bcc003cc3b5e929e7e32dc?s=96&#038;d=mm&#038;r=g\",\"caption\":\"Viktoria Endres\"},\"url\":\"https:\\\/\\\/cms.core-way.de\\\/pt\\\/author\\\/viktoria-endres\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"O princ\u00edpio ativo Tulisokibart: Esperan\u00e7a para os doentes com DII? - coreway","description":"O ingrediente ativo tulisokibart demonstrou em estudos ajudar os doentes com doen\u00e7a inflamat\u00f3ria intestinal cr\u00f3nica. Esta \u00e9 a situa\u00e7\u00e3o atual","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cms.core-way.de\/pt\/o-ingrediente-ativo-tulisokibart-uma-esperanca-para-os-doentes-com-ced\/","og_locale":"pt_PT","og_type":"article","og_title":"Der Wirkstoff Tulisokibart: Eine Hoffnung f\u00fcr Patient:innen mit CED? - coreway","og_description":"Der Wirkstoff Tulisokibart konnte in Studien, Patient:innen mit chronisch-entz\u00fcndlichen Darmerkrankungen, helfen. Das ist der aktuelle Stand","og_url":"https:\/\/cms.core-way.de\/pt\/o-ingrediente-ativo-tulisokibart-uma-esperanca-para-os-doentes-com-ced\/","og_site_name":"coreway","article_published_time":"2025-09-29T14:47:14+00:00","article_modified_time":"2025-09-29T14:47:20+00:00","og_image":[{"width":1366,"height":768,"url":"https:\/\/cms.core-way.de\/wp-content\/uploads\/2025\/09\/Bilder-Blogbeitraege-5.png","type":"image\/png"}],"author":"Viktoria Endres","twitter_card":"summary_large_image","twitter_misc":{"Escrito por":"Viktoria Endres","Tempo estimado de leitura":"8 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/cms.core-way.de\/der-wirkstoff-tulisokibart-eine-hoffnung-fuer-patientinnen-mit-ced\/#article","isPartOf":{"@id":"https:\/\/cms.core-way.de\/der-wirkstoff-tulisokibart-eine-hoffnung-fuer-patientinnen-mit-ced\/"},"author":{"name":"Viktoria Endres","@id":"https:\/\/cms.core-way.de\/#\/schema\/person\/c3801c6b8c6c5095157d831a44019e1f"},"headline":"Der Wirkstoff Tulisokibart: Eine Hoffnung f\u00fcr Patient:innen mit CED?","datePublished":"2025-09-29T14:47:14+00:00","dateModified":"2025-09-29T14:47:20+00:00","mainEntityOfPage":{"@id":"https:\/\/cms.core-way.de\/der-wirkstoff-tulisokibart-eine-hoffnung-fuer-patientinnen-mit-ced\/"},"wordCount":1255,"commentCount":0,"publisher":{"@id":"https:\/\/cms.core-way.de\/#organization"},"image":{"@id":"https:\/\/cms.core-way.de\/der-wirkstoff-tulisokibart-eine-hoffnung-fuer-patientinnen-mit-ced\/#primaryimage"},"thumbnailUrl":"https:\/\/cms.core-way.de\/wp-content\/uploads\/2025\/09\/Bilder-Blogbeitraege-5.png","keywords":["Behandlung von CED","Behandlung von Colitis ulcerosa","Behandlung von Morbus Crohn","Behandlungsm\u00f6glichkeiten","CED","chronisch-entz\u00fcndliche Darmerkrankungen","Colitis ulceroa","IBD","Morbus Crohn","Therapie","Treatment","Tulisokibart","Wirkstoff"],"articleSection":["CED-Wissen &amp; Forschung: Diagnose, Behandlung &amp; Therapien"],"inLanguage":"pt-PT","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/cms.core-way.de\/der-wirkstoff-tulisokibart-eine-hoffnung-fuer-patientinnen-mit-ced\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/cms.core-way.de\/der-wirkstoff-tulisokibart-eine-hoffnung-fuer-patientinnen-mit-ced\/","url":"https:\/\/cms.core-way.de\/der-wirkstoff-tulisokibart-eine-hoffnung-fuer-patientinnen-mit-ced\/","name":"O princ\u00edpio ativo Tulisokibart: Esperan\u00e7a para os doentes com DII? - coreway","isPartOf":{"@id":"https:\/\/cms.core-way.de\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cms.core-way.de\/der-wirkstoff-tulisokibart-eine-hoffnung-fuer-patientinnen-mit-ced\/#primaryimage"},"image":{"@id":"https:\/\/cms.core-way.de\/der-wirkstoff-tulisokibart-eine-hoffnung-fuer-patientinnen-mit-ced\/#primaryimage"},"thumbnailUrl":"https:\/\/cms.core-way.de\/wp-content\/uploads\/2025\/09\/Bilder-Blogbeitraege-5.png","datePublished":"2025-09-29T14:47:14+00:00","dateModified":"2025-09-29T14:47:20+00:00","description":"O ingrediente ativo tulisokibart demonstrou em estudos ajudar os doentes com doen\u00e7a inflamat\u00f3ria intestinal cr\u00f3nica. Esta \u00e9 a situa\u00e7\u00e3o atual","breadcrumb":{"@id":"https:\/\/cms.core-way.de\/der-wirkstoff-tulisokibart-eine-hoffnung-fuer-patientinnen-mit-ced\/#breadcrumb"},"inLanguage":"pt-PT","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cms.core-way.de\/der-wirkstoff-tulisokibart-eine-hoffnung-fuer-patientinnen-mit-ced\/"]}]},{"@type":"ImageObject","inLanguage":"pt-PT","@id":"https:\/\/cms.core-way.de\/der-wirkstoff-tulisokibart-eine-hoffnung-fuer-patientinnen-mit-ced\/#primaryimage","url":"https:\/\/cms.core-way.de\/wp-content\/uploads\/2025\/09\/Bilder-Blogbeitraege-5.png","contentUrl":"https:\/\/cms.core-way.de\/wp-content\/uploads\/2025\/09\/Bilder-Blogbeitraege-5.png","width":1366,"height":768},{"@type":"BreadcrumbList","@id":"https:\/\/cms.core-way.de\/der-wirkstoff-tulisokibart-eine-hoffnung-fuer-patientinnen-mit-ced\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cms.core-way.de\/"},{"@type":"ListItem","position":2,"name":"Der Wirkstoff Tulisokibart: Eine Hoffnung f\u00fcr Patient:innen mit CED?"}]},{"@type":"WebSite","@id":"https:\/\/cms.core-way.de\/#website","url":"https:\/\/cms.core-way.de\/","name":"via central","description":"","publisher":{"@id":"https:\/\/cms.core-way.de\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cms.core-way.de\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"pt-PT"},{"@type":"Organization","@id":"https:\/\/cms.core-way.de\/#organization","name":"via central","url":"https:\/\/cms.core-way.de\/","logo":{"@type":"ImageObject","inLanguage":"pt-PT","@id":"https:\/\/cms.core-way.de\/#\/schema\/logo\/image\/","url":"https:\/\/cms.core-way.de\/wp-content\/uploads\/2023\/09\/Black-And-White-Aesthetic-Minimalist-Modern-Simple-Typography-Coconut-Cosmetics-Logo-5.png","contentUrl":"https:\/\/cms.core-way.de\/wp-content\/uploads\/2023\/09\/Black-And-White-Aesthetic-Minimalist-Modern-Simple-Typography-Coconut-Cosmetics-Logo-5.png","width":500,"height":500,"caption":"coreway"},"image":{"@id":"https:\/\/cms.core-way.de\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.instagram.com\/core.way\/","https:\/\/www.linkedin.com\/company\/92284357"]},{"@type":"Person","@id":"https:\/\/cms.core-way.de\/#\/schema\/person\/c3801c6b8c6c5095157d831a44019e1f","name":"Viktoria Endres","image":{"@type":"ImageObject","inLanguage":"pt-PT","@id":"https:\/\/secure.gravatar.com\/avatar\/2d515c89c7924f2d3779db2c7424dc10b0cefc7048bcc003cc3b5e929e7e32dc?s=96&#038;d=mm&#038;r=g","url":"https:\/\/secure.gravatar.com\/avatar\/2d515c89c7924f2d3779db2c7424dc10b0cefc7048bcc003cc3b5e929e7e32dc?s=96&#038;d=mm&#038;r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/2d515c89c7924f2d3779db2c7424dc10b0cefc7048bcc003cc3b5e929e7e32dc?s=96&#038;d=mm&#038;r=g","caption":"Viktoria Endres"},"url":"https:\/\/cms.core-way.de\/pt\/author\/viktoria-endres\/"}]}},"uagb_featured_image_src":{"full":["https:\/\/cms.core-way.de\/wp-content\/uploads\/2025\/09\/Bilder-Blogbeitraege-5.png",1366,768,false],"thumbnail":["https:\/\/cms.core-way.de\/wp-content\/uploads\/2025\/09\/Bilder-Blogbeitraege-5-150x150.png",150,150,true],"medium":["https:\/\/cms.core-way.de\/wp-content\/uploads\/2025\/09\/Bilder-Blogbeitraege-5-300x169.png",300,169,true],"medium_large":["https:\/\/cms.core-way.de\/wp-content\/uploads\/2025\/09\/Bilder-Blogbeitraege-5-768x432.png",768,432,true],"large":["https:\/\/cms.core-way.de\/wp-content\/uploads\/2025\/09\/Bilder-Blogbeitraege-5-1024x576.png",1024,576,true],"wpdr-feat-thumb":["https:\/\/cms.core-way.de\/wp-content\/uploads\/2025\/09\/Bilder-Blogbeitraege-5-450x600.png",450,600,true],"delrecpe-structured-data-1_1":["https:\/\/cms.core-way.de\/wp-content\/uploads\/2025\/09\/Bilder-Blogbeitraege-5-500x500.png",500,500,true],"delrecpe-structured-data-4_3":["https:\/\/cms.core-way.de\/wp-content\/uploads\/2025\/09\/Bilder-Blogbeitraege-5-500x375.png",500,375,true],"delrecpe-structured-data-16_9":["https:\/\/cms.core-way.de\/wp-content\/uploads\/2025\/09\/Bilder-Blogbeitraege-5-480x270.png",480,270,true],"1536x1536":["https:\/\/cms.core-way.de\/wp-content\/uploads\/2025\/09\/Bilder-Blogbeitraege-5.png",1366,768,false],"2048x2048":["https:\/\/cms.core-way.de\/wp-content\/uploads\/2025\/09\/Bilder-Blogbeitraege-5.png",1366,768,false],"trp-custom-language-flag":["https:\/\/cms.core-way.de\/wp-content\/uploads\/2025\/09\/Bilder-Blogbeitraege-5-18x10.png",18,10,true],"bdpp-medium":["https:\/\/cms.core-way.de\/wp-content\/uploads\/2025\/09\/Bilder-Blogbeitraege-5-640x480.png",640,480,true]},"uagb_author_info":{"display_name":"Viktoria Endres","author_link":"https:\/\/cms.core-way.de\/pt\/author\/viktoria-endres\/"},"uagb_comment_info":0,"uagb_excerpt":"Der Wirkstoff Tulisokibart: Eine Hoffnung f\u00fcr Patient:innen mit CED? Morbus Crohn und Colitis ulcerosa verlaufen bei jedem Patienten und jeder [&hellip;]","_links":{"self":[{"href":"https:\/\/cms.core-way.de\/pt\/wp-json\/wp\/v2\/posts\/4292","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cms.core-way.de\/pt\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cms.core-way.de\/pt\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cms.core-way.de\/pt\/wp-json\/wp\/v2\/users\/10"}],"replies":[{"embeddable":true,"href":"https:\/\/cms.core-way.de\/pt\/wp-json\/wp\/v2\/comments?post=4292"}],"version-history":[{"count":9,"href":"https:\/\/cms.core-way.de\/pt\/wp-json\/wp\/v2\/posts\/4292\/revisions"}],"predecessor-version":[{"id":4336,"href":"https:\/\/cms.core-way.de\/pt\/wp-json\/wp\/v2\/posts\/4292\/revisions\/4336"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cms.core-way.de\/pt\/wp-json\/wp\/v2\/media\/4297"}],"wp:attachment":[{"href":"https:\/\/cms.core-way.de\/pt\/wp-json\/wp\/v2\/media?parent=4292"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cms.core-way.de\/pt\/wp-json\/wp\/v2\/categories?post=4292"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cms.core-way.de\/pt\/wp-json\/wp\/v2\/tags?post=4292"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}